Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: The subject matter disclosed herein relates to a method of treating glioblastoma (GBM) in a subject in need thereof, the method comprising determining one or more GBM subtypes in a GBM sample via a pathway-based classifier approach and administering to the subject a pharmaceutically effective amount of an agent capable of modifying the activity of the biological pathways associated with the one or more GMB subtypes.

Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: The subject matter described herein relates to a method of regulating protein kinase activity by allosteric modifications such as prolyl hydroxylation.

Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: The present disclosure provides, in one embodiment, a method of treating or preventing an ID2 protein-related disease in a patient at risk of developing or having such a disease by administering to the patient a composition in an amount and for a time sufficient to increase degradation of HIF? in a cell affected by the ID2 protein-related disease in the patent and/or to decrease half-life of HIF? in the cell affected by the ID2 protein-related disease in the patient, as compared to an untreated cell affected by the ID2 protein-related disease.

Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: The present disclosure provides a method of classifying a glioma in a patient by identifying with respect to the glioma, isocitrate dehydrogenase genes (IDH) mutation status, DNA methylation cluster, RNA cluster, telomere length, telomere maintenance, and at least one biomarker, and based in the identifications, classifying the glioma as IDH mutant/G-CIMP low glioma type, IDH mutant/G-CIMP high glioma type, IDH mutant/Codel glioma type, DH wild type/Classic like glioma type, IDH wild type/Mesenchymal-like glioma type, IDH wild type/LGm6-GBM glioma type, or PA-like glioma type.

Abstract: The present disclosure provides, in one embodiment, a method of treating or preventing an ID2 protein-related disease in a patient at risk of developing or having such a disease by administering to the patient a composition in an amount and for a time sufficient to increase degradation of HIF? in a cell affected by the ID2 protein-related disease in the patent and/or to decrease half-life of HIF? in the cell affected by the ID2 protein-related disease in the patient, as compared to an untreated cell affected by the ID2 protein-related disease.

Abstract: High-grade gliomas are the most common brain tumors in humans and are essentially incurable. The defining hallmark of these high-grade gliomas is the presence within the tumor mass of highly tumorigenic cellular subpopulations that fuel tumor aggressiveness. Identification of the molecular mechanisms remains elusive. Therefore, there is a need for diagnostic markers to accurately determine the type of glioma and appropriate treatment. Gene delivery vehicles are provided that comprise an oncogene, IRES-Cre-ER cassette and a gene encoding an oligonucleotide that inhibits p53 including shp53. Methods are also provided for determining a diagnosis and for treatment of non-aggressive and aggressive gliomas.

Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: Techniques for treating a subject with M-GBM and recurrent GBM are provided. Example methods include obtaining at least two M-GBM tumor samples from different locations within a patient, extracting genomic DNA from each of the tumor samples, and determining whether the subject has a mutation in PI3K-AKT-mTOR (PAM) pathway in both DNA samples. If a mutation in PAM pathway is present in each of the isolated DNA samples, the method can further include treating the subject with an effective amount of an agent that inhibits the PAM pathway. Pharmaceutical agents and kits for use in the treatment of M-GBM and recurrent GBM are also provided.

Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: High-grade gliomas are the most common brain tumors in humans and are essentially incurable. The defining hallmark of these high-grade gliomas is the presence within the tumor mass of highly tumorigenic cellular subpopulations that fuel tumor aggressiveness. Identification of the molecular mechanisms remains elusive. Therefore, there is a need for diagnostic markers to accurately determine the type of glioma and appropriate treatment. Gene delivery vehicles are provided that comprise an oncogene, IRES-Cre-ER cassette and a gene encoding an oligonucleotide that inhibits p53 including shp53. Methods are also provided for determining a diagnosis and for treatment of non-aggressive and aggressive gliomas.

Abstract: The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

Abstract: The invention provides for methods for treating nervous system cancers in a subject. The invention further provides methods for treating nervous system tumor cell invasion, migration, proliferation, and angiogenesis associated with nervous system tumors.